Delafloxacin meglumine
CAS No. 352458-37-8
Delafloxacin meglumine ( ABT492 meglumine | RX-3341 meglumine | WQ-3034 meglumine )
产品货号. M21582 CAS No. 352458-37-8
德拉沙星葡甲胺是一种广谱氟喹诺酮类抗生素。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥145 | 有现货 |
|
| 10MG | ¥236 | 有现货 |
|
| 25MG | ¥471 | 有现货 |
|
| 50MG | ¥854 | 有现货 |
|
| 100MG | ¥1557 | 有现货 |
|
| 200MG | ¥2223 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥259 | 有现货 |
|
生物学信息
-
产品名称Delafloxacin meglumine
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述德拉沙星葡甲胺是一种广谱氟喹诺酮类抗生素。
-
产品描述Delafloxacin meglumine is a broad-spectrum fluoroquinolone antibiotic.(In Vivo):Delafloxacin (the total daily doses vary from 0.156 to 640 mg/kg/24 h, subcutaneous injection) is highly effective against S. aureus. Against all four strains are observed a decrease of 1.5 to 2.2 log10 CFU in organism burden from untreated controls at even the lowest dose studied, and for two strains (MW2 and R2527) there is net bactericidal activity at the lowest dose. At the maximal doses studied, there is a >4-log10 kill from initial burden for all S. aureus strains.Delafloxacin (2.5, 10, 40, and 160 mg/kg; subcutaneous injection, 24 h) has moderate terminal elimination half-life (t1/2=0.68 h, 0.79 h, 0.69 h and 1.0 h for 2.5 mg/kg, 10 mg/kg, 40 mg/kg, and 160 mg/kg, respectively).
-
体外实验——
-
体内实验Delafloxacin (the total daily doses vary from 0.156 to 640 mg/kg/24 h, subcutaneous injection) is highly effective against S. aureus. Against all four strains are observed a decrease of 1.5 to 2.2 log10 CFU in organism burden from untreated controls at even the lowest dose studied, and for two strains (MW2 and R2527) there is net bactericidal activity at the lowest dose. At the maximal doses studied, there is a >4-log10 kill from initial burden for all S. aureus strains.Delafloxacin (2.5, 10, 40, and 160 mg/kg; subcutaneous injection, 24 h) has moderate terminal elimination half-life (t1/2=0.68 h, 0.79 h, 0.69 h and 1.0 h for 2.5 mg/kg, 10 mg/kg, 40 mg/kg, and 160 mg/kg, respectively). Animal Model:Mice with a neutropenic murine lung infection model (fourS. aureus, four S. pneumoniae, and fourK. pneumoniae strains)Dosage:The total daily doses vary from 0.156 to 640 mg/kg/24 h Administration:0.03 to 160 mg/kg are administered every 6 h (q6h) to infected mice by subcutaneous injectionResult:Inhibited S. aureus strains ATCC 29213, ATCC 33591, MW2, R2527 with MICs of 0.008, 0.008, 0.004, and 0.004 mg/L, respectively.Inhibited S. pneumoniae strains ATCC 10813, ATCC 49619, 145, and 1329 with MICs of 0.03, 0.125, 0.016, and 0.016 mg/L, respectively.Inhibited K. pneumonia strains ATCC 43816, 4105, 4110, and 81-1260A with MICs of 0.06, 1, 0.5, and 0.06 mg/L, respectively.Animal Model:Neutropenic miceDosage:2.5, 10, 40, and 160 mg/kg; 0.2 mL Administration:Subcutaneous injection; 24 h Result:The maximum drug concentrations (Cmax) concentrations ranged from 2 to 71 mg/L. AUC0-∞ values ranged from 2.8 to 152 mg?h/L and were linear across the 2.5- to 160-mg dosing range. The elimination half-life (t1/2) ranged from 0.7 to 1 h.
-
同义词ABT492 meglumine | RX-3341 meglumine | WQ-3034 meglumine
-
通路GPCR/G Protein
-
靶点Antibacterial
-
受体Bacterial
-
研究领域——
-
适应症Pneumonia
化学信息
-
CAS Number352458-37-8
-
分子量635.97
-
分子式C25H29ClF3N5O9
-
纯度>98% (HPLC)
-
溶解度DMSO:6.4 mg/mL (10.06 mM);H2O:50 mg/mL (78.62 mM; Need ultrasonic)
-
SMILESCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Lepak AJ et al. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus Streptococcus pneumoniae and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9.
产品手册
关联产品
-
C-215
C-215 是一种新型分枝杆菌膜蛋白大 3 (MmpL3) 抑制剂,针对结核分枝杆菌的 MIC90 为 16 uM。
-
Pefloxacin
Pefloxacin 是一种抗菌剂,通过抑制 DNA 旋转酶(拓扑异构体)来防止细菌 DNA 复制。
-
FSL 1
TLR2/6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.
021-51111890
购物车()
sales@molnova.cn

